Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

Phase 2 Study

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30688-5 ◽

2018 ◽

Vol 19 (1) ◽

pp. 87-100 ◽

Cited By ~ 151

Author(s):

Angelo Di Leo ◽

Stephen Johnston ◽

Keun Seok Lee ◽

Eva Ciruelos ◽

Per E Lønning ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Mtor Inhibition ◽

Double Blind Placebo ◽

Faculty of 1000 evaluation for Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717985574.793472568 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomised Controlled ◽

Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”

10.1158/1538-7445.sabcs17-p3-12-01 ◽

2018 ◽

Cited By ~ 1

Author(s):

P Sánchez-Rovira ◽

AL Hirschberg ◽

M Gil-Gil ◽

S Antolín-Novoa ◽

L García-Estévez ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Early Stage ◽

Controlled Study ◽

Adjuvant Setting ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

10.1158/1538-7445.sabcs16-ot1-04-05 ◽

2017 ◽

Author(s):

HS Rugo ◽

KC Drumea ◽

M Campone ◽

A Barnadas ◽

O Petrenciuc ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70026-3 ◽

2013 ◽

Vol 14 (3) ◽

pp. 228-235 ◽

Cited By ~ 112

Author(s):

John FR Robertson ◽

Jean-Marc Ferrero ◽

Hugues Bourgeois ◽

Hagen Kennecke ◽

Richard H de Boer ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomised Controlled ◽

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps621 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS621-TPS621 ◽

Cited By ~ 1

Author(s):

Hope S. Rugo ◽

Rui Li ◽

Oana Petrenciuc ◽

Amily Zhang ◽

Robert E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Faculty Opinions recommendation of Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732279400.793559076 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Mtor Inhibition ◽

Double Blind Placebo ◽

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdw365.89 ◽

2016 ◽

Vol 27 ◽

pp. vi97 ◽

Cited By ~ 1

Author(s):

H. Rugo ◽

O. Petrenciuc ◽

A. Zhang ◽

R. Li ◽

R.E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

European Journal of Cancer ◽

10.1016/j.ejca.2015.10.012 ◽

2016 ◽

Vol 53 ◽

pp. 144-154 ◽

Cited By ~ 19

Author(s):

Konstantinos Tryfonidis ◽

Gul Basaran ◽

Jan Bogaerts ◽

Marc Debled ◽

Luc Dirix ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

European Organisation ◽

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Cited By ~ 2

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽